1. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, et al. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J 2019;43:398-406.
[CROSSREF] [PUBMED] [PMC]
2. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
[CROSSREF] [PUBMED] [PMC]
3. Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017;135:659-70.
[CROSSREF] [PUBMED]
4. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529-39.
[CROSSREF] [PUBMED]
5. Al-Sofiani ME, Derenbecker R, Quartuccio M, Kalyani RR. Aspirin for primary prevention of cardiovascular disease in diabetes: a review of the evidence. Curr Diab Rep 2019;19:107.
[CROSSREF] [PUBMED]
6. Kim JD, Park CY, Ahn KJ, Cho JH, Choi KM, Kang JG, et al. Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. Atherosclerosis 2014;234:146-51.
[CROSSREF] [PUBMED]
7. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-35.
[CROSSREF] [PUBMED]
8. Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med 2014;127:95.
[CROSSREF]
9. Uehara S, Hirayama A. Effects of cilostazol on platelet function. Arzneimittelforschung 1989;39:1531-4.
[PUBMED]
10. Yeung J, Holinstat M. Newer agents in antiplatelet therapy: a review. J Blood Med 2012;3:33-42.
[PUBMED] [PMC]
11. Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Kume S, et al. Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin. Diabetes Care 2013;36:e92-3.
[CROSSREF] [PUBMED] [PMC]
12. Shen H, Herzog W, Drolet M, Pakyz R, Newcomer S, Sack P, et al. Aspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol 2009;104:606-12.
[CROSSREF] [PUBMED] [PMC]
13. Schwartz KA. Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem 2006;42:81-110.
[CROSSREF] [PUBMED]
14. Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009;95:1225-9.
[CROSSREF] [PUBMED]
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
[CROSSREF] [PUBMED]
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
[CROSSREF] [PUBMED]
17. Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015;11:133-48.
[CROSSREF] [PUBMED] [PMC]
18. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004;11:600-2.
[CROSSREF] [PUBMED]
19. Kariyazono H, Nakamura K, Arima J, Ayukawa O, Onimaru S, Masuda H, et al. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 2004;15:157-67.
[CROSSREF] [PUBMED]
20. Van Oosterom N, Barras M, Cottrell N, Bird R. Platelet function assays for the diagnosis of aspirin resistance. Platelets 2022;33:329-38.
[CROSSREF] [PUBMED]
21. Park JS, Kim YJ. The clinical effects of cilostazol on atherosclerotic vascular disease. Korean Circ J 2008;38:441-5.
[CROSSREF]
22. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94.
[CROSSREF] [PUBMED]
23. Ohta M, Satoh K, Fukasawa I, Hosokawa K, Oonishi T, Nakagomi J, et al. Assessment of cilostazol inhibition using whole blood samples: comparison of three platelet function tests. Yamanashi Med J 2017;32:27-37.
24. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007;71:1867-72.
[CROSSREF] [PUBMED]
25. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur J Neurol 2010;17:434-42.
[CROSSREF] [PUBMED]
26. Kim CW, Yun JW, Bae IH, Park YH, Jeong YS, Park JW, et al. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100(R) and Multiplate(R) whole blood aggregometer
in vitro,
ex vivo and FeCl3-induced thrombosis models
in vivo. Thromb Res 2011;127:565-70.
[PUBMED]
27. Satoh K, Fukasawa I, Kanemaru K, Yoda S, Kimura Y, Inoue O, et al. Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring. Thromb Res 2012;130:616-21.
[CROSSREF] [PUBMED]
28. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000;59:347-56.
[CROSSREF] [PUBMED]
29. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531-40.
[CROSSREF] [PUBMED] [PMC]
30. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-90.
[CROSSREF] [PUBMED]
31. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103.
[CROSSREF] [PUBMED]
32. Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl 2008;10(suppl_A):A28-34.
[CROSSREF]
33. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
[CROSSREF] [PUBMED]
34. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011;12:647-55.
[CROSSREF] [PUBMED]
35. Hong S, Nam M, Little BB, Paik S, Lee K, Woo J, et al. Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. Heart Vessels 2019;34:1758-68.
[CROSSREF] [PUBMED]
36. Kim BJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LK, et al. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke 2020;51:931-7.
[CROSSREF] [PUBMED]
37. Hsieh CJ, Wang PW. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009;73:948-54.
[CROSSREF] [PUBMED]
38. O’Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, et al. The effects of cilostazol on exerciseinduced ischaemia-reperfusion injury in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2009;37:326-35.
[CROSSREF] [PUBMED]
39. Kim MA, Kim CJ, Seo JB, Chung WY, Kim SH, Zo JH, et al. The effect of aspirin on C-reactive protein in hypertensive patients. Clin Exp Hypertens 2011;33:47-52.
[CROSSREF] [PUBMED]
40. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117-38.
[PUBMED]